Association Between Neutrophil-to-Lymphocyte Ratio/Lymphocyte-to-Monocyte Ratio and In-Hospital Clinical Outcomes in Ischemic Stroke Treated with Intravenous Thrombolysis

References

• Group NIoNDaSr-PSS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587. doi:10.1056/NEJM199512143332401
   PubMed Web of Science ®Google Scholar
• Bluhmki E, Chamorro Á, Dávalos A, et al. Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8(12):1095–1102. doi:10.1016/S1474-4422(09)70264-9
   PubMed Web of Science ®Google Scholar
• Saver JL, Smith EE, Reeves MJ, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480–2488. doi:10.1001/jama.2013.6959
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282. doi:10.1016/S0140-6736(07)60149-4
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646):1303–1309. doi:10.1016/S0140-6736(08)61339-2
   PubMed Web of Science ®Google Scholar
• Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 2010;9(9):866–874. doi:10.1016/S1474-4422(10)70165-4
   PubMed Web of Science ®Google Scholar
• Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40(7):2442–2449. doi:10.1161/STROKEAHA.109.548602
   PubMed Web of Science ®Google Scholar
• Ahmed NDA, Eriksson N, Ford GA, et al.; SITS Investigators. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol. 2010;67(9):1123–1130. doi:10.1001/archneurol.2010.210
   PubMedGoogle Scholar
• Kharitonova TV, Melo TP, Andersen G, Egido JA, Castillo J, Wahlgren N. Importance of cerebral artery recanalization in patients with stroke with and without neurological improvement after intravenous thrombolysis. Stroke. 2013;44(9):2513–2518. doi:10.1161/STROKEAHA.111.000048
   PubMed Web of Science ®Google Scholar
• Strbian D, Ahmed N, Wahlgren N, et al. Trends in door-to-thrombolysis time in the safe implementation of stroke thrombolysis registry: effect of center volume and duration of registry membership. Stroke. 2015;46(5):1275–1280. doi:10.1161/STROKEAHA.114.007170
   PubMed Web of Science ®Google Scholar
• Schuhmann MK, Stoll G, Bieber M, et al. CD84 links T cell and platelet activity in cerebral thrombo-inflammation in acute stroke. Circ Res. 2020;127(8):1023–1035. doi:10.1161/CIRCRESAHA.120.316655
   PubMed Web of Science ®Google Scholar
• Parikh NS, Merkler AE, Iadecola C. Inflammation, autoimmunity, infection, and stroke: epidemiology and lessons from therapeutic intervention. Stroke. 2020;51(3):711–718. doi:10.1161/STROKEAHA.119.024157
   PubMed Web of Science ®Google Scholar
• Stoll G, Nieswandt B. Thrombo-inflammation in acute ischaemic stroke - implications for treatment. Nat Rev Neurol. 2019;15(8):473–481. doi:10.1038/s41582-019-0221-1
   PubMed Web of Science ®Google Scholar
• Lux D, Alakbarzade V, Bridge L, et al. The association of neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio with 3-month clinical outcome after mechanical thrombectomy following stroke. J Neuroinflammation. 2020;17(1):60. doi:10.1186/s12974-020-01739-y
   PubMed Web of Science ®Google Scholar
• Gong P, Liu Y, Gong Y, et al. The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke. J Neuroinflammation. 2021;18(1):51. doi:10.1186/s12974-021-02090-6
   PubMed Web of Science ®Google Scholar
• Switonska M, Slomka A, Korbal P, et al. Association of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio with treatment modalities of acute ischaemic stroke: a pilot study. Medicina. 2019;55(7):342. doi:10.3390/medicina55070342
   PubMed Web of Science ®Google Scholar
• Switonska M, Piekus-Slomka N, Slomka A, Sokal P, Zekanowska E, Lattanzi S. Neutrophil-to-lymphocyte ratio and symptomatic hemorrhagic transformation in ischemic stroke patients undergoing revascularization. Brain Sci. 2020;10(11):771. doi:10.3390/brainsci10110771
   PubMed Web of Science ®Google Scholar
• Ying Y, Yu F, Luo Y, et al. Neutrophil-to-lymphocyte ratio as a predictive biomarker for stroke severity and short-term prognosis in acute ischemic stroke with intracranial atherosclerotic stenosis. Front Neurol. 2021;12:705949. doi:10.3389/fneur.2021.705949
   PubMed Web of Science ®Google Scholar
• Lee SH, Jang MU, Kim Y, et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict reperfusion and prognosis after endovascular treatment of acute ischemic stroke. J Pers Med. 2021;11(8):696.
   PubMed Web of Science ®Google Scholar
• Liu YL, Wu ZQ, Qu JF, et al. High neutrophil-to-lymphocyte ratio is a predictor of poor short-term outcome in patients with mild acute ischemic stroke receiving intravenous thrombolysis. Brain Behav. 2020;10(12):e01857. doi:10.1002/brb3.1857
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang M, Hao Y, et al. Early prediction of poor outcome despite successful recanalization after endovascular treatment for anterior large vessel occlusion stroke. World Neurosurg. 2018;115:e312–e21. doi:10.1016/j.wneu.2018.04.042
   PubMed Web of Science ®Google Scholar
• Lyden PBT, Tilley B, Welch KM, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25(11):2220–2226. doi:10.1161/01.STR.25.11.2220
   PubMed Web of Science ®Google Scholar
• Adams HP, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41. doi:10.1161/01.STR.24.1.35
   PubMed Web of Science ®Google Scholar
• Fazekas FCJ, Hurtig HI, Hurtig HI, Zimmerman RA, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–356. doi:10.2214/ajr.149.2.351
   PubMed Web of Science ®Google Scholar
• Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a Phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781–788. doi:10.1016/S1474-4422(17)30253-3
   PubMed Web of Science ®Google Scholar
• Weng Y, Hu J, Ren J, et al. Dynamic neutrophil-lymphocyte ratios predict short-term prognostic outcome of thrombolysis in patients with acute ischemic stroke. Neurotox Res. 2021;39(5):1678–1687. doi:10.1007/s12640-021-00382-6
   PubMed Web of Science ®Google Scholar
• Chen CT, Li LH, Su PY, et al. Neutrophil-to-lymphocyte ratio in predicting neurologic outcome of patients with acute ischemic stroke treated with intravenous thrombolytics. J Chin Med Assoc. 2022;85(1):102–108. doi:10.1097/JCMA.0000000000000599
   PubMed Web of Science ®Google Scholar
• Jian Z, Liu R, Zhu X, et al. The involvement and therapy target of immune cells after ischemic stroke. Front Immunol. 2019;10:2167. doi:10.3389/fimmu.2019.02167
   PubMed Web of Science ®Google Scholar
• Petrovic-Djergovic D, Goonewardena SN, Pinsky DJ. Inflammatory Disequilibrium in Stroke. Circ Res. 2016;119(1):142–158. doi:10.1161/CIRCRESAHA.116.308022
   PubMed Web of Science ®Google Scholar
• Berchtold D, Priller J, Meisel C, Meisel A. Interaction of microglia with infiltrating immune cells in the different phases of stroke. Brain Pathol. 2020;30(6):1208–1218. doi:10.1111/bpa.12911
   PubMed Web of Science ®Google Scholar
• Xu S, Lu J, Shao A, Zhang JH, Zhang J. Glial cells: role of the immune response in ischemic stroke. Front Immunol. 2020;11:294. doi:10.3389/fimmu.2020.00294
   PubMed Web of Science ®Google Scholar
• Khoshnam SE, Winlow W, Farzaneh M, Farbood Y, Moghaddam HF. Pathogenic mechanisms following ischemic stroke. Neurol Sci. 2017;38(7):1167–1186. doi:10.1007/s10072-017-2938-1
   PubMed Web of Science ®Google Scholar
• Ao LY, Yan YY, Zhou L, et al. Immune cells after ischemic stroke onset: roles, migration, and target intervention. J Mol Neurosci. 2018;66(3):342–355. doi:10.1007/s12031-018-1173-4
   PubMed Web of Science ®Google Scholar
• Planas AM. Role of immune cells migrating to the ischemic brain. Stroke. 2018;49(9):2261–2267. doi:10.1161/STROKEAHA.118.021474
   PubMed Web of Science ®Google Scholar
• Rayasam A, Hsu M, Kijak JA, et al. Immune responses in stroke: how the immune system contributes to damage and healing after stroke and how this knowledge could be translated to better cures? Immunology. 2018;154(3):363–376. doi:10.1111/imm.12918
   PubMed Web of Science ®Google Scholar
• Xue J, Huang W, Chen X, et al. Neutrophil-to-lymphocyte ratio is a prognostic marker in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2017;26(3):650–657. doi:10.1016/j.jstrokecerebrovasdis.2016.11.010
   PubMed Web of Science ®Google Scholar
• Kim JY, Kawabori M, Yenari MA. Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets. Curr Med Chem. 2014;21(18):2076–2097. doi:10.2174/0929867321666131228205146
   PubMed Web of Science ®Google Scholar
• Zhang J, Ren Q, Song Y, et al. Prognostic role of neutrophil-lymphocyte ratio in patients with acute ischemic stroke. Medicine. 2017;96(45):e8624. doi:10.1097/MD.0000000000008624
   PubMed Web of Science ®Google Scholar
• Liesz A, Suri-Payer E, Veltkamp C, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15(2):192–199. doi:10.1038/nm.1927
   PubMed Web of Science ®Google Scholar
• Ren X, Akiyoshi K, Dziennis S, et al. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci. 2011;31(23):8556–8563. doi:10.1523/JNEUROSCI.1623-11.2011
   PubMed Web of Science ®Google Scholar
• Ma G, Pan Z, Kong L, Du G. Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis: potential mechanisms, targets, therapeutic drugs and biomarkers. Int Immunopharmacol. 2021;90:107216. doi:10.1016/j.intimp.2020.107216
   PubMed Web of Science ®Google Scholar
• Won S, Lee JK, Stein DG. Recombinant tissue plasminogen activator promotes, and progesterone attenuates, microglia/macrophage M1 polarization and recruitment of microglia after MCAO stroke in rats. Brain Behav Immun. 2015;49:267–279. doi:10.1016/j.bbi.2015.06.007
   PubMed Web of Science ®Google Scholar
• Ruhnau J, Schulze J, Dressel A, Vogelgesang A. Thrombosis, neuroinflammation, and poststroke infection: the multifaceted role of neutrophils in stroke. J Immunol Res. 2017;2017:5140679. doi:10.1155/2017/5140679
   PubMed Web of Science ®Google Scholar
• Zhang R, Wu X, Hu W, et al. Neutrophil-to-lymphocyte ratio predicts hemorrhagic transformation in ischemic stroke: a meta-analysis. Brain Behav. 2019;9(9):e01382. doi:10.1002/brb3.1382
   PubMed Web of Science ®Google Scholar
• Brooks SD, Spears C, Cummings C, et al. Admission neutrophil-lymphocyte ratio predicts 90 day outcome after endovascular stroke therapy. J Neurointerv Surg. 2014;6(8):578–583. doi:10.1136/neurintsurg-2013-010780
   PubMed Web of Science ®Google Scholar
• Karamchandani RR, Strong D, Rhoten JB, et al. Age and discharge modified Rankin score are associated with 90-day functional outcome after basilar artery occlusion treated with endovascular therapy. Interv Neuroradiol. 2021;27(4):531–538. doi:10.1177/1591019920987040
   PubMed Web of Science ®Google Scholar
• ElHabr AK, Katz JM, Wang J, et al. Predicting 90-day modified Rankin Scale score with discharge information in acute ischaemic stroke patients following treatment. BMJ Neurol Open. 2021;3(1):e000177. doi:10.1136/bmjno-2021-000177
   PubMedGoogle Scholar
• Thompson MP, Reeves MJ. Abstract 168: assessing the utility of the Modified Rankin Scale (mRS) at discharge to predict day 90 outcomes in acute stroke registries. Circulation. 2012;5:A168.
   Google Scholar